Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Morphologic diagnosis of CAMR, by light \&/or electron microscopy any time after transplantation~* Current or previously documented donor-specific antibody (DSA) and/or focal or diffuse peritubular capillary C4d staining by immunohistochemistry~* eGFR\>25 ml/min~Exclusion Criteria:~* Diagnosis of malignancy within a year prior to enrollment (except cured cutaneous basal cell or squamous cell carcinoma).~* Lack of evidence of antibody involvement~* Pregnancy, lactation, or refusal to use birth control in women of child bearing potential~* Active infection, or history of HIV~* History of liver or thoracic transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Acthar (Type: EXPERIMENTAL): The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.

Based on this trial design, predict the completion outcome and termination type (if applicable).